Abatacept in the Treatment of Uveitis

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Uveitis
Interventions
DRUG

Abatacept

"Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.~Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years."

Trial Locations (1)

97239

Oregon Health & Science University, Portland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Oregon Health and Science University

OTHER

NCT01279954 - Abatacept in the Treatment of Uveitis | Biotech Hunter | Biotech Hunter